TRP channel–associated factors are a novel protein family that regulates TRPM8 trafficking and activity

Dimitra Gkika,1 Loic Lemonnier,1 George Shapovalov,1 Dmitri Gordienko,1 Céline Poux,2 Michela Bernardini,1,6 Alexandre Bokhobza,1 Gabriel Bidaux,3 Cindy Degerny,4 Kathye Verremann,2 Basma Guarmit,5 Mohamed Benahmed,5 Yvan de Launoit,4 Rene J.M. Bindels,7 Alessandra Fiorio Pla,1,6 and Natalia Prevarskaya1

1Inserm U1003, Équipe labellisée par la Ligue Nationale Contre le Cancer, Université des Sciences et Technologies de Lille (USTL), 59655 Villeneuve d’Ascq Cedex, France
2Centre national de la Recherche Scientifique (CNRS) UMR 8198 and Laboratoire de Génétique & Évolution des Populations Végétales (GEPV), Université des Sciences et Technologies de Lille (USTL), 59655 Villeneuve d’Ascq Cedex, France
3Laboratoire Biophotonique Cellulaire Fonctionnelle, Institut de Recherche Interdisciplinaire, USR3078 Centre National de la Recherche Scientifique, Parc scientifique de la Haute Borne, Villeneuve d’Ascq, F-59655 France
4CNRS UMR 8161, Institut de Biologie de Lille, Université de Lille—Nord de France, Institut Pasteur de Lille, 59019 Lille Cedex, France
5Inserm, Institut National de la Santé et de la Recherche Médicale U895, Centre Méditerranéen de Médecine Moléculaire, Hôpital d’Archet, 06204 Nice, France
6Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy
7Department of Physiology, Radboud University Nijmegen Medical Centre, 6500HB Nijmegen, Netherlands

TRPM8 is a cold sensor that is highly expressed in the prostate as well as in other non-temperature-sensing organs, and is regulated by downstream receptor–activated signaling pathways. However, little is known about the intracellular proteins necessary for channel function. Here, we identify two previously unknown proteins, which we have named “TRP channel–associated factors” (TCAFs), as new TRPM8 partner proteins, and we demonstrate that they are necessary for channel function. TCAF1 and TCAF2 both bind to the TRPM8 channel and promote its trafficking to the cell surface. However, they exert opposing effects on TRPM8 gating properties. Functional interaction of TCAF1/TRPM8 also leads to a reduction in both the speed and directionality of migration of prostate cancer cells, which is consistent with an observed loss of expression of TCAF1 in metastatic human specimens, whereas TCAF2 promotes migration. The identification of TCAFs introduces a novel mechanism for modulation of TRPM8 channel activity.

Introduction

Transient receptor potential (TRP) channels form a large family of cation channels involved in a diverse range of physiological functions, and are expressed in almost all cell types (Clapham, 2003). They play important roles ranging from Ca2+ absorption, vasorelaxation, cell death, mechanotransduction, and hearing, to the mediation of pH, heat, taste, osmolarity, and pain sensations. Dysfunctions of TRP channels have been linked to several diseases (Nilius et al., 2007). Among members of the TRP channel family, the function of TRPM8 could be considered one of the most intriguing. Although it was initially cloned from the prostate (Tsavaler et al., 2001; Stein et al., 2004) and is expressed in tissues not affected by ambient temperature fluctuations such as the prostate, testis, and bladder (Tsavaler et al., 2001; Stein et al., 2004), this channel is mainly known as the principal detector of environmental cold (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007).

TRPM8 expression is strongly up-regulated in numerous cancers such as that of the prostate, but is dramatically reduced during metastasis in androgen-independent prostate cancers (Tsavaler et al., 2001; Henshall et al., 2003; Yee et al., 2010). This pattern of variation of TRPM8 expression makes it an interesting candidate both as a diagnostic marker for the detection of certain cancers and as a prognostic marker in evaluating the}

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

Supplemental Material can be found at:
/content/suppl/2015/01/02/jcb.201402076.DC1.html
outcome of these cancers (Zhang and Barritt, 2006). In addition, it could play a protective role in metastatic prostate cancer (Gkika and Prevarskaya, 2011), as recent data show that it blocks the migration of prostate cancer cells (Yang et al., 2009; Gkika et al., 2010; Zhu et al., 2011). Thus, although TRPM8 is considered to be a promising target for pharmaceutical, immunological, and genetic interventions for the treatment of prostate cancer (Zhang and Barritt, 2006), it is first necessary to better understand its biological function and the physiological modulators in this organ.

Besides cool temperatures, TRPM8 is also activated by several chemical compounds that elicit a sensation of cold, of which the best known are menthol, eucalyptol, and the supercooling icilin (McKemy et al., 2002; Peier et al., 2002; Behrendt et al., 2004; Chuang et al., 2004; Beck et al., 2007; Bödding et al., 2007). Chemical agents generally serve as positive allosteric modulators. More specifically, because the activation of TRPM8 is also voltage dependent, these agonists shift the activation threshold toward more negative potentials, enabling the channel to open at higher than normal temperatures, whereas antagonists exert their effect by shifting the threshold of TRPM8 activation toward more positive potentials (Brauchi et al., 2004; Voets et al., 2004; Mülkiä et al., 2007).

In the absence of the aforementioned physical and chemical stimuli, TRPM8 could be kept in readiness in a dynamic pool of vesicles under the cell surface, awaiting the appropriate signal for plasma membrane insertion and channel activation (Veliz et al., 2010; Latorre et al., 2011). This dynamic TRPM8 pool could be activated by intracellular factors known to modulate TRPM8 activity, such as second messengers generated during the activation of surface-receptor–coupled signaling pathways (Bavencoffe et al., 2010, 2011; Latorre et al., 2011; Yadun and Rohacs, 2012; Zhang et al., 2012; Shapovalov et al., 2013a). However, the intracellular elements involved in controlling the stabilization of the channel on the cell surface and the subsequent amplification of its activity are currently unknown.

Several studies show that TRP channels can be regulated by partner proteins affecting their trafficking to the plasma membrane (Vogel et al., 2007) and/or their channel activity (van de Graaf et al., 2003, 2006; Gkika et al., 2004, 2006a,b; Sinkins et al., 2004; Chang et al., 2005; Köttgen and Walz, 2005). Indeed, the regulated translocation of TRP channels appears to be a key mechanism for the gating of constitutively active subunits, as well as for enhancing the activity of stimulus-gated channels (Shapovalov et al., 2013a). Thus, the identification of the molecular components implicated in this cellular process is of great importance in understanding not only the regulatory mechanisms of TRP channels but also their function.

To identify and characterize the molecular determinants of TRPM8 regulation, we performed a screening for TRPM8 partner proteins in the prostate, where the channel is primarily expressed. As a result, we have identified a previously uncharacterized protein family as a first example of TRPM8 regulators.

Results
Identification of the TRP channel-associated factors (TCAFs): a family of TRPM8 partner proteins
To identify TRPM8 regulatory proteins, which have not been identified until now, we performed a GST pull-down assay to screen lysates of healthy mouse prostates, with the N-terminal and C-terminal cytosolic tails of TRPM8 as bait. Fourier transform ion cyclotron resonance mass spectrometry (FTMS) revealed mouse Experimental Autoimmune Prostatitis Antigen 2 (EAPA2) as a protein interacting with TRPM8. The full list of peptides interacting with TRPM8 cytosolic tails is presented in Tables S1 and S2. As EAPA2 is not known in humans, we searched for highly homologous proteins using National Center for Biotechnology Information (NCBI) Blast. Two proteins of unknown function, Fam115A, consisting of 921 amino acids (NP_055534), and Fam115C, consisting of 845 amino acids (NP_001123497), were thus identified and named TCAF1 and -2. The alignment of these two proteins with EAPA2 (hereafter renamed TCAF3) revealed 51% and 57% of identity, respectively. Once substitutions by similar residues were taken into account, the similarity between TCAF3 and TCAF1 or TCAF2 reached 69% and 66%, respectively (see Fig. 2), which suggests that they may have a common origin and belong to the same group of genes.

Indeed, a phylogenetic analysis of TCAF1, TCAF2, and TCAF3 revealed the presence of a putative gene family. Given the sequences available in GenBank, we determined two duplication events (Fig. 1 A), supported by both posterior probabilities (PP; Bayesian method) and bootstrap supports (BP; maximum likelihood method [ML]). In mammals, up to three highly similar genes were found (TCAF1, TCAF2, and TCAF3), whereas only one gene copy was seen in fish, amphibians, and birds. The mammalian TCAF1 and TCAF2 sequences are phylogenetically closer to each other than to the other vertebrate sequences. Therefore the first duplication event most likely occurred during mammalian evolution. Given the poor taxon sampling available in the database, it was not possible to precisely determine the period of duplication. A second duplication event appears to have taken place during rodent evolution to generate the TCAF3 gene (Fig. 1 A).

Although mouse TCAF3 is mainly expressed in the prostate, nothing is known about the tissue distribution of the newly identified human homologues. We thus examined TCAF1 and TCAF2 expression in several human tissue samples using quantitative real-time PCR (qPCR). Both transcripts were predominantly expressed in the prostate (Fig. 1 B), similar to TCAF3 in rodents and TRPM8 in humans and rodents.

Both TCAF1 and TCAF2 interact directly with the TRPM8 channel
To verify the association of human TCAF1 and TCAF2 proteins with TRPM8, we cloned TCAF1 and TCAF2 and studied their interaction with TRPM8 by GST pull-down assays. In vitro-translated [35S]methionine-labeled TCAF1 and TCAF2 strongly interacted with the TRPM8 N-terminal tail (GST-M8N) and to
Identification of TRPM8 partner proteins • Gkika et al.

present on the beads and was detected in the precipitated complex (IP) with TCAF1 and TCAF2. No band was detected in precipitated complexes from cells that were not transfected with TRPM8 or cells immunoblotted for another protein such as actin, which indicates the specificity of the interaction (Fig. 3 B). TCAF interactions with additional TRP channels were also analyzed.

Figure 1. Bayesian phylogenetic tree of the vertebrate TCAF1/TCAF2/TCAF3 genes and tissue expression pattern of the human homologues. (A) The maximum likelihood tree was similar but for one node: the cow and horse FAM115C sequences were sister groups. The phylogenetic reconstruction displays two duplication events, one during the early period of mammalian evolution and the other during rodent evolution. The scale bar represents the number of expected changes per site. (B) Analysis of TRPM8, TCAF1, and TCAF2 mRNA expression levels by qPCR in several human tissues. Values are expressed relative to 18S rRNA expression, and further normalized to TRPM8 levels in the prostate. Values are presented as means of three experimental repeats ± SEM (error bars; n = 3 for a single experiment).
revealed significant FRET between TRPM8 and TCAF1 or TCAF2 (Fig. 3 F). In control experiments on HEK cells expressing TRPM8-mTurquoise2 and free SYFP2, no significant variation of mTurquoise2 lifetime was detected (Fig. 3 F), and calculated EFRET was found to be below the confidence threshold of 1%. These observations altogether with biochemical analysis of interaction confirmed in living cells that TCAFs are partners of the TRPM8 channels. TCAFs exert opposing regulatory effects on TRPM8-mediated currents

To assess the functional effect of TCAF1–TCAF2 interactions with the TRPM8 channel in human prostate cells, we performed a series of patch-clamp experiments. The silencing of native TCAFs by siRNAs to TCAF1 or -2 was monitored by RT-PCR after 72 h, and specifically abolished TCAF1 or -2 expression by coimmunoprecipitation to check whether TCAF is a TRPM8-exclusive partner. Altogether, these results show that TCAFs are potential partner proteins for other TRP channels, such as TRPV6 and the short isoform of TRPM2 (Fig. S1, A and B).

Confocal imaging of the cells transfected with HA-tagged TCAF1 or myc-tagged TCAF2 and labeled with TRPM8 antibodies confirmed that both TCAFs colocalize with TRPM8 (Fig. S2, A and B). Direct interaction between the two proteins in living cells was confirmed by means of Förster resonance energy transfer (FRET) using the time-domain fluorescence lifetime imaging microscopy (TD FLIM). After the 24-h transfection, HEK cells expressing TRPM8-mTurquoise2 and TCAF-SYFP2 (Fig. 3 C) were analyzed using the time-correlated single photon counting (TCSPC) of the donor fluorescence (Fig. 3, D and E), and the lifetime of mTurquoise2 was computed on a pixel-by-pixel basis (Fig. 3, D and E). Statistical analysis revealed significant FRET between TRPM8 and TCAF1 or TCAF2 (Fig. 3 F). In control experiments on HEK cells expressing TRPM8-mTurquoise2 and free SYFP2, no significant variation of mTurquoise2 lifetime was detected (Fig. 3 F), and calculated EFRET was found to be below the confidence threshold of 1%. These observations altogether with biochemical analysis of interaction confirmed in living cells that TCAFs are partners of the TRPM8 channels.

Figure 2. Human homologues of TCAF3. Alignment of hFAM115A (TCAF1) and hFAM115C (TCAF2) with the murine EAPA2 (TCAF3) protein. Amino acid residues are highlighted in black when present in the three proteins and in gray when they are present in only two of them. TCAFs exert opposing regulatory effects on TRPM8-mediated currents

To assess the functional effect of TCAF1–TCAF2 interactions with the TRPM8 channel in human prostate cells, we performed a series of patch-clamp experiments. The silencing of native TCAFs by siRNAs to TCAF1 or -2 was monitored by RT-PCR after 72 h, and specifically abolished TCAF1 or -2 expression.
Figure 3. TCAF1 and TCAF2 interact and colocalize with TRPM8. (A) GST pull-down assay using [35S]methionine-labeled TCAF1 or TCAF2 protein and GST or GST fused to the TRPM8 N-terminal tail (GST-M8N) or C-terminal tail (GST-M8C). (B) Cells transfected with HA-tagged TCAF1 or myc-tagged TCAF2 with [HEK-M8] or without [HEK] his-tagged full-length TRPM8, and total lysates (TL) were used for immunoprecipitation and subsequent immunoblot analysis. Immunoprecipitation of the channel was confirmed by immunoblotting for TRPM8, and the communoprecipitation of TCAF1 or TCAF2 proteins was detected using an anti-HA or anti-myc antibody, respectively, on the immunoprecipitated complex [IP]. No communoprecipitation was detected in control immunoblots for actin. The black lines on the HA-TCAF1 blots indicate the removal of intervening lanes for presentation purposes. (C–F) TCAF1/2-to-TRPM8 binding was assessed by measuring FRET with TM FLIM in HEK293 cells after a 24-h transfection. The TCSPC approach was chosen to achieve a good spatial resolution, which would allow discriminating TRPM8-ER localization. (C) An example of concomitant expression of TRPM8-mTurquoise2 (cyan) and TCAF1-SYFP2 (yellow). (D and E) Representative FRET-FLIM images for TRPM8-mTurquoise alone and for TRPM8-mTurquoise + TCAF1-SYFP2, respectively. Grayscale-coded fluorescence images of the donor of FRET (left images in D and E; fluorescence intensity [FI] is given in arbitrary units [a.u.]) were analyzed by the phasor plot method (Phasor) to compute FLIM images (mean) showing the mean lifetime (ns; right images of D and E). The outlines define the regions of interest for which mean lifetime of the donor of fluorescence was calculated. Bars, 10 µm. (F) Chart representing the mean lifetime of TRPM8-mTurquoise2 alone, coexpressed with the negative control SYFP2, or with TCAF1-SYFP2 or TCAF2-SYFP2. FRET efficiency [E_{FRET}] is shown on the top of the chart. Values are presented as means ± SD (error bars). ***, P < 0.001.
at both the mRNA (Fig. 4 A) and protein levels, as seen after transfection with vectors expressing tagged proteins (Fig. 4 B). We then examined the role of the TCAFs in TRPM8 trafficking using biotin labeling. Cell-surface biotinylation experiments showed that both TCAFs enhanced channel expression in the biotinylated fraction when compared with cotransfection with
an empty vector (Fig. 4 C), whereas siRNA to TCAF1 significantly decreased channel abundance on the plasma membrane compared with control siRNAs (siLuc; Fig. 4 D).

In terms of channel activity, TCAF1 silencing in these cells at 37°C induced a decrease in basal TRPM8 activity from 88.2 ± 15.5 to 58.9 ± 5.3 pA/pF (Fig. 4 E). A similar inhibitory effect was observed on I_{TRPM8} currents evoked by cold, icilin, and menthol, which decreased from 158.7 ± 37.3, 111.6 ± 38.5, and 54.9 ± 16.4 pA/pF in control cells (n = 12) to 22.8 ± 13.3, 40.8 ± 10.1, and 32.3 ± 11.1 pA/pF, respectively, in cells transfected with TCAF1 siRNA (siTCAF1; n = 8). In contrast, TCAF2 silencing led to an increase in basal I_{TRPM8} amplitude from 88.2 ± 15.5 to 187.4 ± 47.9 pA/pF (Fig. 4 F), whereas responses to cold, icilin, and menthol were increased from 158.7 ± 37.3, 111.6 ± 38.5, and 54.9 ± 16.4 pA/pF in control cells (n = 12) to 341.3 ± 131.9, 164.2 ± 42.3, and 115.7 ± 62.2 pA/pF, respectively, in cells treated with TCAF2 siRNA (siTCAF2; n = 4). A histogram summarizing these results at both +100 and −100 mV is presented in Fig. S2 C, and shows similar effects of partner proteins silencing at both potentials. The overexpression of TCAF1 and TCAF2 had an opposite effect to that of the siRNAs, confirming the activating role of TCAF1 and the inhibitory role of TCAF2 on TRPM8 activity (n = 5; Fig. 4, G and H; and Fig. S2 D). These results clearly show that TCAF1 and -2 can modulate TRPM8 basal activity, therefore suggesting a potential role of this interaction in controlling calcium homeostasis. Moreover, TCAF1 and -2 effects on TRPM8 activity were equally observed for all tested potentials, thus precluding the existence of a voltage-dependent component to these interactions (Fig. 4 H).

The C-terminal tail of TCAF1 plays a critical role in TRPM8 regulation

TCAF1 and -2 both bind to TRPM8 and augment its targeting to the plasma membrane, while having different effects on channel activity. We therefore searched the protein sequences of TCAF1 and TCAF2 for domains that could explain this disparity. A low homology with the PI3K domain was predicted using the Conserved Domains software tool from NCBI on the C-terminal homology with the PI3K domain was predicted using the Conserved Domains software tool from NCBI. Analysis of native TRPM8, we examined how the level of TCAF1 or TCAF2 expression would affect menthol-induced [Ca^{2+}] responses in LNCaP cells, which naturally express TRPM8 (Valero et al., 2011, 2012). We first confirmed TRPM8 expression and activity in these cells by using siRNAs targeting the channel (Fig. S2, E and F). Next, we compared [Ca^{2+}] responses in wortmannin-treated TCAF1-transfected cells (n = 5); and 142.7 ± 25.9, 172.7 ± 29.9, and 130 ± 23.4 pA/pF in control (n = 4), and 188.7 ± 70.8, 191.6 ± 80.1, and 135.6 ± 34.5 pA/pF in wortmannin-treated TCAF1-transfected cells (n = 6).

We then examined the effect of this domain on TRPM8 trafficking to the plasma membrane. Cotransfection of TRPM8 with TCAF1 or TCAF1_{AP13K} followed by cell-surface biotinylation showed that both TCAF1 and its truncated form enhanced channel expression in the biotinylated fraction compared with cotransfection with the empty vector (Fig. 5 F).

TCAF1 and TCAF2 exert opposing regulatory effects on endogenous TRPM8 activity

To analyze whether TCAF1 and TCAF2 are involved in the regulation of native TRPM8, we examined how the level of TCAF1 or TCAF2 expression would affect menthol-induced [Ca^{2+}] responses in LNCaP cells, which naturally express TRPM8 (Valero et al., 2011, 2012). We first confirmed TRPM8 expression and activity in these cells by using siRNAs targeting the channel (Fig. S2, E and F). Next, we compared [Ca^{2+}] responses to 200 µM menthol in fluo-4–loaded control LNCaP cells, LNCaP cells overexpressing either TCAF1 or TCAF2, and LNCaP cells pretreated with either control siRNA (siLuc), TCAF1 siRNA, or TCAF2 siRNA (Fig. 6). The siRNA experiments were also performed in human epithelial prostate cells, Ep156T (Fig. S3). Our results revealed that both the amplitude of the response and its temporal profile depended on the level of TCAF1 and TCAF2 expression. In control (Fig. 6 A) and TCAF1-overexpressing (Fig. 6 B) LNCaP cells, as well as in LNCaP (Fig. 6 E) and Ep156T (Fig. S3 A) cells pretreated with siLuc or siTCAF2 (Fig. 6 G and Fig. S3 C), menthol triggered a high-amplitude [Ca^{2+}] transient. The magnitude of this oscillatory response was significantly reduced in cells overexpressing TCAF2 (Fig. 6 C) and was increased after pretreatment with siTCAF2 (Fig. 6 G and Fig. S3 C). In LNCaP cells overexpressing TCAF1, an initial phase of the menthol-induced response was followed by several long-period [Ca^{2+}] oscillations of smaller amplitude (Fig. 6 B), whereas pretreatment with siTCAF1 virtually abolished all the response in both LNCaP (Fig. 6 F) and Ep156T (Fig. S3 B). As the temporal pattern of the [Ca^{2+}] response to TRPM8 activation is complex, to quantify the effects of TCAF overexpression
pretreated with siLuc with that pretreated with either siTCAF1 or siTCAF2. Menthol-induced [Ca^2+]i responses were directly correlated with changes in TCAF1 expression but inversely correlated with changes in TCAF2 expression, which indicates and siRNAs, we compared the fluo-4 signal during the first 18 min after menthol application in control LNCaP cells with that in LNCaP cells overexpressing TCAF1 or TCAF2 (Fig. 6 D), and the signal in LNCaP (Fig. 6 H) and Ep156T cells (Fig. S3 D) pretreated with siLuc with that pretreated with either siTCAF1 or siTCAF2. Menthol-induced [Ca^2+]i responses were directly correlated with changes in TCAF1 expression but inversely correlated with changes in TCAF2 expression, which indicates
Figure 6. The menthol-induced response of endogenous TRPM8 is modulated by TCAF1 and TCAF2. [A–G] Changes of [Ca^{2+}]i in response to the activation of TRPM8 with 200 µM menthol were monitored using an x-y time-series imaging of fluo-4 fluorescence in control LNCaP cells (A), LNCaP cells overexpressing TCAF1 (B) or TCAF2 (C), and LNCaP cells pretreated with siLuc (E), siTCAF1 (F), or siTCAF2 (G). Images were acquired at 0.6 Hz from confocal optical slices <4 µm. The fluorescence intensity (F) was normalized to the averaged fluorescence intensity before menthol application (F0). Relative changes in fluorescence intensity (ΔF/F0), averaged within each of 10 cells denoted by the numbers on the images (left), are plotted over time. Menthol application is depicted on the 3D plots by vertical cyan bars. The galleries below the plots demonstrate the images of fluo-4 fluorescence captured at times indicated above the images. Bar diagram plots compare masses of the fluo-4 signal, ∫ΔF/F0, during the first 18 min after menthol application (D) in LNCaP cells overexpressing TCAF1 (n = 48) or TCAF2 (n = 51) versus control LNCaP cells (n = 62), and in LNCaP cells (H) pretreated with siTCAF1 (n = 56) or siTCAF2 (n = 42) versus LNCaP cells pretreated with siLuc (n = 52). Values are expressed as means ± SEM (error bars). ***, P < 0.001; **, P < 0.01.
that TRPM8 channel opening is facilitated by TCAF1 and suppressed by TCAF2.

**TCAF1 binding introduces new kinetic states to TRPM8 single channel activity**

Next, we checked for any potential effect of TCAF1/TCAF2 on TRPM8 activity at the single channel level. These experiments were performed in HEK 293 cells expressing TRPM8 under the control of a tetracycline-inducible promoter (HEK-293T; Thebault et al., 2005) in order to limit the contamination of our recordings by the activity of other channels. Control HEK-293T cells as well as cells transfected with TCAF1 or TCAF2 plasmids were subjected to a short tetracycline induction as described. Then, TRPM8 activity was measured in cell-attached configuration by first recording activity at room temperature followed by the application of 100 µM menthol (see Fig. S4 for sample traces). While comparing activity in control and TCAF1-transfected cells, two types of activity became apparent (Fig. 7 A). The first type, characterized by short, separate openings, was most common to control cells (19 control and 4 TCAF1-bound traces), whereas the second type exhibited the clustering of openings without any apparent increase in opening duration and was prevalent in TCAF1-transfected cells (5 control and 29 TCAF1-bound traces). In contrast, cells transfected with TCAF2 and induced according to an identical protocol exhibited virtually no TRPM8 activity (only 4 out of 31 traces exhibited TRPM8 opening), leading us to conclude that TCAF2 silences the TRPM8 channel (unpublished data).

To further study how TCAF1 binding modifies TRPM8 gating properties, the acquired traces were scrutinized for the appearance of multiple conductance levels, and those containing single-channel activity (four control and three TCAF1-bound) were individually analyzed, as described previously (Qin and Li, 2004; Fernández et al., 2011). Fig. 7 (B–D) summarizes dwell-time distributions, kinetic rates, and energy landscapes representing typical control and TCAF1-bound TRPM8 activity at room temperature and after stimulation by menthol. Interestingly, stimulation of TRPM8 activity by menthol only led to changes in the energy of the closed states, correspondingly increasing the frequency of channel openings while preserving the overall model. However, the effect of TCAF1 was qualitatively different. Although the analysis of control activity showed that the gating of TRPM8 alone could be reliably described by a relatively simple model, containing three closed and one open kinetic states (the 3c1o model; two upper panels on Fig. 7, C and D), this was not the case for the TCAF1-bound activity, suitable representation of which required a more complex model with four closed and two open states (the 4c2o model; two lower panels on Fig. 7, C and D). Fig. S5 compares the fits of the TRPM8 activity by the 4c2o and 3c1o kinetic models. Analysis of the activity of TRPM8 alone (Fig. S5, A and C) shows that both models yield identical log likelihood with additional states of the 4c2o model exhibiting virtually zero occupancy, which validates the simpler 3c1o model. On the contrary, analysis of the activity of TRPM8 interacting with TCAF1 (Fig. S5, B and D) shows significantly larger changes in log likelihood as well as a nontrivial occupancy of the additional states in the 4c2o model, emphasizing the significance of these additional kinetic states in activity of TRPM8. In other words, the binding of TCAF1 to the TRPM8 channel introduces new kinetic states that are necessary for a satisfactory description of TRPM8 gating, which implies a direct binding of TCAF1 to TRPM8.

**TCAF1 but not TCAF2 shows expression patterns similar to TRPM8 during carcinogenesis, and slows down cell migration**

Given the fact that TRPM8 is a marker for prostate cancer, we investigated by qPCR whether the expression of its interacting proteins, TCAF1 and TCAF2, was also associated with prostate cancer development. We initially studied TRPM8, TCAF1, and TCAF2 expression in healthy and cancerous human prostate resection samples. Patients were included in the study when both tumoral and nontumoral (healthy) tissue could be obtained from the same individual. TRPM8 and TCAF1 expression were significantly increased in cancerous samples when compared with healthy ones (10 and 5 times, respectively; n = 7–10 for each condition, P < 0.05), whereas no difference was observed for the TCAF2 transcript (Fig. 8 A).

We then assessed the variation in expression of these transcripts between localized prostate cancer and metastasis to the bone marrow of patients previously subjected to androgen ablation therapy. qPCR analysis showed a clear decrease in both TRPM8 and TCAF1 expression in metastatic samples in comparison with localized prostate cancer (n = 7–10 for each condition, P < 0.01). TCAF2 expression remained unchanged, as before (Fig. 8 B).

To verify that the similar expression patterns of TRPM8 and TCAF1 during carcinogenesis were also important at the functional level, we investigated the role of TCAF1 in prostate cell migration by performing time-lapse microscopy experiments on either PC3 or LNCaP prostate cancer cells (Fig. 9).

TRPM8 overexpression significantly decreases the cell migration speed, and this effect is exacerbated in the presence of icilin stimulation (Fig. 9, A and B), in accordance with our previous results on wound healing and transwell assays (Gkika et al., 2010). Moreover, TCAF1 overexpression significantly decreased the cell migration speed (Fig. 9, A and B) even in the absence of TRPM8 (Fig. 9 B). However, when overexpressed together with TRPM8, we observed a further significant decrease in the speed, which indicates that the TCAF1 effect is, at least partially, mediated by TRPM8 (Fig. 9, B and C). To test whether the inhibition of cell migration was due to the PI3K domain of TCAF1, we performed cell migration assay in cells overexpressing TCAF1<sub>ΔPI3K</sub> (Fig. 9, A and C). We indeed observed a significant increase in the migration speed of cells transfected with TCAF1<sub>ΔPI3K</sub> versus TCAF1-transfected cells (Fig. 9, A and C); this effect is further increased in the presence of TRPM8 (Fig. 9 C). These results are in agreement with modulation of TRPM8-mediated current by PI3K domain of TCAF1 (Fig. 5, D and E). Although TCAF2 inhibits the migration speed in the absence of TRPM8, it significantly increases the speed when TRPM8 is expressed (Fig. 9 C).
Finally, we studied the effect of native TCAFs on cell migration with an siRNA approach. As expected, TCAF1 down-regulation increases migration, which interestingly occurs by acting on the directional persistence index (Fig. 9 E) and not on the speed (Fig. 9 D). The effect on directional migration index of siTCAF1 is exacerbated in the presence of TRPM8 (Fig. 9 E).
as well as electrophysiological measurements that the TCAFs interact directly with TRPM8, exerting opposing effects on channel activity. We have subsequently unraveled the molecular mechanism of TCAF action on TRPM8 activity using directed mutagenesis, biochemical assays, and single-channel analysis, demonstrating: (1) a domain responsible for their distinct channel regulation activities, (2) the effect of the TCAFs on channel plasma membrane trafficking, and (3) the qualitative effect on TRPM8 activity via the introduction of new kinetic states during gating. At the cellular level, the functional TCAF1–TRPM8 interaction leads to the inhibition of cell speed, which is also supported by the loss of expression of these proteins in human metastatic specimens. Indeed these two proteins are mainly expressed in the prostate, as demonstrated by the qPCR screening of human tissues.

Addressing the molecular mechanisms responsible for the regulation of TRPM8 activity and expression by the TCAFs, we have shown that the TCAFs interact mainly with the TRPM8 N-terminal tail. Our data imply that both proteins are critical for TRPM8 function because their silencing prevents the channel’s insertion into the plasma membrane. GST pull-down experiments with in vitro translated TCAFs strongly point to the direct binding of TCAFs to TRPM8, which is further supported by the introduction of new kinetic states to TRPM8 single-channel kinetics in the presence of the TCAF1 protein, whereas TCAF2 completely silences the channel while retaining it in plasma membrane. Interestingly, this situation closely resembles the role that β subunits play in regulating T-type calcium channels through the direct interaction of involved proteins (Gerster et al., 1999). To understand the opposing modulatory effects of TCAF1 and TCAF2, one has to look at sequence differences between the proteins, such as the loss of the C-terminal extremity in TCAF2. However, the removal of this region in TCAF1 (TCAF1PI3K) did not completely mimic the behavior of TCAF2, and although TCAF1PI3K overexpression indeed leads to a decrease in ITTRPM8 amplitude when compared with TCAF1, the extent of this decrease is significantly lower than that observed with TCAF2 overexpression. The presence in this region of a PI3K homology domain coupled with our observation that (1) a PI3K inhibitor (wortmannin) inhibits TRPM8 activity and that (2) this sensitivity to wortmannin is abolished in cells overexpressing TCAF1PI3K strongly suggest that the regulatory role of the TCAFs also involves phosphorylation. In this model, both TCAF1 and TCAF2 proteins bind to TRPM8, affecting its expression on the plasma membrane. The presence of a functional PI3K homology domain, however, is required to make the channel fully active. Moreover this domain is also critical for cell motility because TCAF1PI3K transfection partially reverts the inhibitory effect exerted by TCAF1. However it should be noted that because the TCAF1PI3K mutant implies the deletion of TCAF1 C terminus, the loss of function may not be due only to the disruption of the PI3K-specific enzymatic activity. More experiments are thus needed to characterize the respective roles of TCAF1 functional enzymatic domain and C terminus.

Our phylogenetic analysis revealed that human TCAF1 and -2 are homologues of rodent TCAF3 (EAPA2) and that these three proteins form a new protein family originating from two duplication events. TCAF3 was identified in 2006 by mass
different regulatory effects on TRPM8. In this regard, the relative abundance of TCAFs and their competition in binding TRPM8 seems to be critical in the physiological regulation of the channel activity. This is further supported by the differences in TCAF’s effect on single channel activity (the addition of one open state for TCAF1), while their binding to the channel is similar, as shown in the GST pull-down and coimmunoprecipitation assays. Moreover, the expression of TCAF1 is universally and closely

spectrometric analysis as a new prostate-specific protein regulated by androgens in mice (Fujimoto et al., 2006). At the time, the function of TCAF3 was unknown and no homologues had been identified in humans. Our discovery of the TCAF–TRPM8 interaction allows us to assign a role to this important family of proteins, often coexpressed with the TRPM8 channel. Interestingly, although TCAF1 and -2 share a common phylogenetic origin and exhibit a high degree of homology, they exert completely

Figure 9. TCAF functional role in prostate cancer cell migration. (A) Representative migration plots of control (top left) and TRPM8-overexpressing cells (top right) or TRPM8 cotransfected with wild-type TCAF1 (bottom left) or truncated TCAF1 lacking the PI3K domain (TCAF1ΔPI3K, bottom right). Each line represents the migration of one cell within a 10-h period. The data shown are from a single representative experiment out of three repeats. For the experiment shown: CNTRL n = 28, TRPM8 n = 58, TRPM8/TCAF1 n = 69, TRPM8/TCAF1ΔPI3K n = 98. (B and C) Bar graphs showing the quantification of cell speed in control nontransfected prostate cancer cells (CNTRL), TRPM8-overexpressing cells (TRPM8), TCAF1-overexpressing cells (TCAF1), TRPM8- and TCAF1-overexpressing cells (TRPM8/TCAF1), and TRPM8 and TCAF1 lacking the PI3K domain (TCAF1ΔPI3K) in the presence or absence of 10 µM icilin. (D–F) Bar graphs showing the quantification of cell speed (D) and the migratory persistence index (E, calculated as indicated in the online materials) in control cells and TRPM8-overexpressing cells in which TCAF1 or TCAF2 are down-regulated (TRPM8/siTCAF1), in the presence or absence of 10 µM icilin (F). Each graph represents the quantification of pooled independent experiments (at least three experiments for each experimental condition). For each experiment, at least 60 cells were followed per condition (*, P < 0.05 relative to CNTRL; § relative to TRPM8). Data are expressed as means ± SEM (error bars).
linked to TRPM8 expression, whereas the expression of TCAF2 is mostly independent and does not exhibit large variations. Although coupling with TCAF2 completely silences TRPM8 activity, its physiological role is not clear in nonovexpressing systems. We speculate that this might be due to the loss of the C-terminal domain in the human TCAF2. This result may be different for other mammalian TCAF2s, as this domain is still present in the genes we used for the phylogenetic analysis.

The highest expression of TRPM8 is in the prostate, where it is suggested to play a role in carcinogenesis (Thébault et al., 2005; Bidaux et al., 2007; Sabnis et al., 2008; Wondergem et al., 2008). Prostate carcinogenesis is commonly associated with major alterations in TRPM8 expression and its signaling pathway (Bavencoffe et al., 2011; Gkika and Prevarskaya, 2011; Prevarskaya et al., 2011; Shapovalov et al., 2013b). In support of this hypothesis, our data reveal that TRPM8 and TCAF1 proteins show similar expression patterns in all tissues studied. Specifically, TCAF1 expression levels increase in cancerous human prostate tissue and drop in metastatic tissue, mirroring TRPM8 levels. However, the expression levels of TCAF2 remain unchanged, which suggests the differential regulation of the two transcripts and reflects their divergence at the functional level. These observations mark TCAF1 as a good candidate for inclusion in the list of well-known prognostic markers such as TRPM8, protein, and the prostate-specific antigen (PSA), which are also deregulated in localized primary prostate cancer, whereas their overexpression is lost again at advanced tumor stages (Schmidt et al., 2006). Moreover, the increased TRPM8 activity and expression linked to the presence of TCAF1 also affects cell migration, as shown by our time lapse video microscopy experiments, and which is in accordance with previous studies linking the overactivity of TRPM8 protein with the reduced motility of prostate cancer cells (Gkika et al., 2010). More specifically, TCAF1 exerts an antimigratory effect on prostate cancer cells by acting on the cell migration, persistence, thus confirming the role of TCAF1 as a TRPM8 activator. However, the complexity of interactions described and the results of our initial GST pull-down, communoprecipitations, and migration assays suggest that TCAFs are partner proteins for other ion channels, such as TRPV6 and the short isoform of TRPM2, which clearly indicates the need for further studies.

Finally, although TCAFs are strongly expressed in the prostate, we show that they are also detected in other tissues, including the brain. It is therefore possible that TCAFs are not merely limited to the role of partner proteins in prostate cells, but are also required and can be therapeutically targeted in other tissues for the stabilization of the expression and modulation of the activity of this channel. For example, TCAFs and their associated molecular pathways could be targets for pain management, according to several recent studies on TRPM8 and allodynia (Chung et al., 2011; Descoeur et al., 2011; Su et al., 2011; Kawashiri et al., 2012; Shapovalov et al., 2013a).

Materials and methods

Phylogenetic analysis

For the three genes TCAF1, TCAF2, and TCAF3, homologous sequences were downloaded from GenBank. Sequences were aligned using Seaview version 4.2.6 (Gouy et al., 2010) and manually adjusted for amino acid alignment. A data matrix containing 2,790 bp was further used for phylogenetic analyses. Any sequence shorter than half the final matrix length was removed, yielding a total of 21 sequences (NM_203396, NM_001009534, BC000609, XM_519454, NM_001132598, NM_029930, XM_342675, XM_00271950, XM_843498, NM_001009954, NM_001130025, XM_519453, XM_539847, XM_001190194, XM_001490518, XM_146174, XM_00119070, XM_002199025, NM_001094966, NM_001089327, and NM_001089927). Phylogenetic reconstructions were performed with the maximum likelihood method (ML) using PhyML 3.0 (Guindon and Gascuel, 2003), and by Bayesian analyses using MrBayes, version 3.1.2 (Huelsenbeck and Ronquist, 2001). The best-fit model under the ML criterion was selected from the “Akaiki Criterion” output of MODEST, version 3.7 (Posada and Crandall, 1998). For the ML analyses, model stability was estimated by 100 nonparametric bootstrap replicates (Felsenstein, 1988). For the Bayesian analyses, the dataset was divided into three partitions according to coding positions. MODEST version 3.7 was used to calculate the best-fit model of sequence evolution for each partition. Two runs of four Markov chains were calculated simultaneously for 4,000,000 generations with equal initial probabilities for all trees and starting with a random tree. Tree sampling frequency was each 100 generations and the consensus tree with posterior probabilities was calculated after removal of the first 25% of the total number of trees generated, corresponding to 10,000 trees. The mean standard deviation of split frequencies between the two independent runs was <0.01.

qPCR

qPCR of mRNA transcripts was done using MESA GREEN qPCR MasterMix Plus (for labeled SYBR Green qPCR Detection System [Bio-Rad Laboratories] and the LightCycler System [Roche]. The sequences of the primers were: for TRPM8, 5′-CCACAGAGAAATGTTGA3′ and 5′-CAGATAGGGCAGCCTGTA3′; for TCAF1, 5′-TACCTACTCATAGTG3′ and 5′-TGGACTGCGATGATGT3′; for TCAF2, 5′-ACCACAGATGGGAACTTG3′ and 5′-GAACCTGTTG-CAGCCTGCCAA3′; for TCAF3, 5′-CCTGAGTCCACCTCCTGTCG3′ and 5′-CAGACCGATGGAAG3′. β-Actin mRNA and 18S rRNA were used as endogenous controls to normalize variations in RNA extraction, the degree of RNA degradation, and the variability of reverse transcription efficiency. To quantify the results, we used the comparative threshold cycle method described by Livak and Schmittgen (2001).

For regular PCR, the following primers were used: for actin, 5′-CACGACAGAAGAGGGGTAATG3′ and 5′-GTGGAGGTCTCACCATAAC-ATGATC3′; for TCAF1, 5′-ATGCGAGGAACCATCCCTC-3′ and 5′-ATGCGAGGAACCATCCCTC-3′; for TCAF2, 5′-ATCCTCACCCACCTGCTC3′ and 5′-ATCCTCACCCACCTGCTC3′; for TCAF3, 5′-ATCCTCACCCACTGCTC3′ and 5′-ATCCTCACCCACTGCTC3′.

Cancer tissue sampling

Prostate tissue samples (prostate adenocarcinoma) were obtained from 15 patients with a mean age of 62.4 yr (ranging from 51 to 70) who underwent radical prostatectomy between January 2004 and June 2008 at the Department of Urology at the Lyon-Sud Hospital Centre. All fragments were snap-frozen and stored in liquid nitrogen until analysis. To ascertain whether the tissue was malignant or nontumoral and to confirm the Gleason score, a histological analysis of frozen sections of each sample was performed by the same pathologist before RNA extraction. Fragments fully made up of tumoral tissue were selected and classified as “tumoral,” whereas samples containing no tumoral tissue were selected and classified as “nontumoral.” Fragments with a mix of normal and tumoral tissue were excluded from the study. Patients were included in the study when both a “tumoral” sample and a “nontumoral” sample could be obtained from the same individual.

In addition, we used nine samples from both localized and metastatic prostate cancer obtained after informed consent from patients with localized (T2a-b) PCa for whom a prostatectomy has been scheduled, and patients with metastatic PCa (M1), which progressed on androgen ablation therapy, were included in a clinical research program (Protocol ID 292L) sponsored by the Hôpitaux Universitaires de Strasbourg. A total volume of 3 ml of bone marrow were aspirated at a scintigraphic-indicated metastatic site. Microscopic observations were made from an aliquot of each bone marrow aspirate to confirm or rule out the presence of metastatic PCa cells. Total RNAs were extracted from small pieces of localized tumor by the use of the RNeasy midi kit (QUIAGEN) and from bone marrow aspirates by the use of the Qiamp RNA blood kit (QUIAGEN) according to the manufacturer’s instructions.
The ethics committee of the faculty of medicine and the state medical board agreed to these investigations, and informed consent was obtained from all patients.

Cloning and siRNA
The coding sequence of the N-terminal tail of TRPM8 (690 aa, S2-K691) was amplified from the TRPM8pmDNA4 plasmid (Theobald et al., 2005) and cloned into the pGExK-2 vector (tac promoter) for chemically inducible, high-level expression of GST-tagged recombinant proteins (GE Healthcare) as a BamHI-XhoI fragment using the primers 5′-CGGGATCCCTCTTGCGGACGAGCTC-3′ and 5′-CCGGTCTGAGCTCTTGCGGACGAGCTC-3′. Similarly, the C-terminal tail of TRPM8 (124 aa, G989K1104) was cloned as a BamHI-XhoI fragment into the tac promoter pGExK-2 vector using the primers 5′-GGGATCCGGTGCGGACGAGCTC-3′ and 5′-CCGGTCTGAGCTCTTGCGGACGAGCTC-3′. The TCAF1 and TCAF2 genes were cloned in the pGEM-T Easy vector (T and SP6 RNA polymerase promoter; Promega) from normal human prostate poly(A)+ RNA (Takara Bio Inc.) using the following primers: for TCAF1, 5′-ATGGGGACCTCGTCTGCTGC-3′ and 5′-TCTACGGGGA-TCTGTGGAGG3′; for TCAF2, 5′-ATGGGGACCTCGTCTGCTGC-3′ and 5′-TCTACGGGGA-TCTGTGGAGG3′. The TCAF1 and TCAF2 genes were purified as per the manufacturer’s instructions. In brief, BL-21 cells were transformed with the pGEXK-2 constructs and cultured in 2XTY medium containing ampicillin (100 µg/ml) at 37°C until the OD reached 0.4–0.6. IPTG was then added to a final concentration of 0.2 mM to induce expression at 30°C for 4 h. The bacteria were pelleted and resuspended in STE buffer (10 mM Tris-HCl, 150 mM NaCl, and 1 mM EDTA, pH 8.0), and the cells were broken by lysozyme (10 mg/ml) incubation. After adequate sonication, the broken cells were pelleted at 13,000 rpm for 30 min at 4°C, and the supernatant was collected for purification. Because pGEX-K2 contains the coding region for GST, we used glutathione Sepharose 4B beads (GE Healthcare) to purify the TRPM8 N and C tails.

TCAF1, TCAF2, and TCAF3 proteins were labeled with [35S] methionine using a reticulocyte lysate system as per the manufacturer’s instructions (Promega), added to purified GST fusion proteins, and immobilized on glutathione Sepharose 4B beads (GE Healthcare) for up to 24 h. After a 2-h incubation at room temperature, the beads were washed extensively and bound proteins were eluted with SDS-PAGE loading buffer, separated on 10% wt/vol SDS-PAGE gels, and visualized by autoradiography.

Preparation of prostate lysates, pull-down assay, and Fourier transform mass spectrometric analysis
The prostate was isolated from two 12-wk-old C57BL/6 male mice, which were sacrificed under 1.5% vol/vol isoflurane anesthesia (Nicholas Piramal Limited). The animal ethics board of the Radboud University Nijmegen approved all animal experimental procedures.

The two prostates were homogenized in homogenization buffer A (HbA; 20 mM, pH 7.4, 5 mM MgCl2, 5 mM/liter NaH2PO4, 1 mM/liter EDTA, 80 mM/liter sucrose, 1 mM/liter PMSF, and 5 g/ml leupeptin and pepstatin). The protein concentration of the homogenates was determined with the Bio-Rad protein assay (Bio-Rad Laboratories). The lysates were subjected to GST pull-down with the TRPM8 N- and C-terminal tail GST fusion proteins while GST alone and another TRP channel (TRPV6-C tail) were used as binding controls (as described in the GST pull-down section).

GST-precipitated proteins were subjected to Fourier transform mass spectrometry (FTMS) in the Radboud Proteomics Centre as described previously (Vogel et al., 2007). In brief, proteins were separated on a conventional 10% SDS-PAGE gel, then the gel was cut into eight slices for digestion by trypsin (two slices per lane, one for high molecular weight and one for low), and after digestion of the protease, peptides were identified using the Mascot (Matrix Science) search engine to search a local version of the SwissProt database (http://www.ncbi.nlm.nih.gov). First-ranked peptides were parsed from the Mascot database search engine and the list of matching peptides was generated using the Peptide Prophet algorithm (University of California, San Francisco) and the DAVID database (http://david.abcc.utoronto.ca) to generate unique first-ranked peptide lists. The full list of interacting peptides can be found in Table S1 and the summary of the number of interacting peptides in Table S2.

Cell culture and transfection
HEK 293 and lymph node carcinoma of prostate (LNCaP) C4-2 cells (provided by F. Viana, Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez, CSIC, Alicante, Spain, and L.A. Pardo, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany) were grown in DMEM and RPMI 1684 (Invitrogen), respectively, supplemented with 10% fetal calf serum (Prolabo, Seromed), 100 units/ml penicillin, 100 mg/ml streptomycin, and 100 mg/ml fungizone. Human epithelial prostate cells, EpH10, were a gift of V. Rotter (Weizmann Institute of Science, Rehovot, Israel) and were grown in MCDB 131 modified by Biological Industries as described previously (Kogan et al., 2006).

Cells were transfected with 2 µg of each construct or 50 nM of siRNA and 0.2 µg of pmx GFP using either Nucleofector (Amaxa) or FU-GENE HD reagent (Roche) and LipHetfect Transfection Reagent (QIAGEN). Control experiments were performed by transfecting the empty vector or siRNA to Luciferase (siLuc).

Cells were used for patch-clamp experiments 24 h after nucleofection and for cell surface biotinylation 48 h after transfection.

Immunoprecipitation and immunoblotting
Cells were cotransfected with a histagged hTRPM8pDNA4 plasmid and human influenza agglutinin (HA)-tagged TCAF1 or myc-tagged TCAF2. Cells were washed twice with PBS, and incubated for 60 min on ice in lysis buffer (1%...
TRITON X-100, 1% sodium deoxycholate, 150 mM NaCl, 10 mM NaKPO4, pH 7.2, and anti-protease cocktail; Sigma-Aldrich). After centrifugation (12,000 g for 10 min at 4°C) of the lysates, protein concentration was determined by the BCA assay (Thermo Fisher Scientific), and equal amount of supernatants were incubated overnight at 4°C with mouse anti-his antibody (Invitrogen) immobilized on protein A/G PLUS agarose beads (Santa Cruz Biotechnology, Inc.). The pellet was washed three times, resuspended in SDS sample buffer, and heated at 37°C for 30 min, separated on 10% wt/vol SDS-PAGE gels, and analyzed by immunoblotting using rabbit anti-HA (1:2,000; Abcam), mouse anti-myc (1:500; Invitrogen), mouse anti-actin (1:5,000; Sigma-Aldrich), mouse anti-calnexin (1:2,000; EMD Millipore), rabbit anti-TRPM8 (1:1,500; Alomone Labs Ltd.), and rabbit anti-TRPV6 (1:200; Santa-Cruz Biotechnology, Inc.) antibodies.

Biotinylation Cells were washed twice with ice-cold PBS containing 1 mM MgCl₂ and 0.5 mM CaCl₂ (PBS-CM) 48 h after transfection, and surface biotinylation was performed by incubating the cells twice for 20 min at 4°C with 1 mg/ml EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce). Subsequently, cells were incubated for 5 min with quenching solution [50 mM NH₄Cl in PBS-CM] at 4°C and rinsed twice with cold PBS-CM. Cells were lysed with 1 ml of lysis buffer (1% Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 10 mM NaKPO₄, pH 7.2, and anti-protease cocktail, Sigma-Aldrich) for 1 h on ice. Lysates were centrifuged at 15,000 × g for 10 min at 4°C. The supernatants were added to 30 µg of Neutravibain-gold beads (Thermo Fisher Scientific). After incubation for 1 h at 4°C, the beads were washed twice with PBS-CM, twice with lysis buffer, and once with 10 mM Tris-HCl, pH 7.5. Finally, biotinylated proteins were eluted with SDS-PAGE loading buffer, separated on 10% wt/vol SDS-PAGE gel, and analyzed by immunoblotting as described for the immunoprecipitation assays with rabbit anti-TRPM8 antibody (1:1,500; Alomone Labs Ltd.).

Immunocytochemistry Cells were cotransfected with his-tagged hTRPM8pcDNA4 plasmid and HA-tagged TCAF1 or myc-tagged TCAF2, and were washed two times, fixed with 4% formaldehyde–1x PBS for 15 min, washed three times, then permeabilized in PBS-gelatin (1.2%) complemented with 0.01% Tween 20 and 100 mM glycine for 30 min at 37°C. Afterward, cells were incubated with primary antibodies: 1:200 goat polyclonal anti-TRPM8 antibody (Anti-Bodies Online), rabbit anti-HA (1:100; Abcam), and mouse anti-myc (1:100; Invitrogen) in PBS-gelatin at 37°C for 1.5 h. After thorough washes, the slides were treated with the corresponding secondary antibodies: donkey Rhodamine Red-X-labeled anti-goat (dilution 1:300; Jackson ImmunoResearch Laboratories, Inc.) and donkey Alexa Fluor 488–labeled anti-rabbit (dilution 1/250; Jackson ImmunoResearch Laboratories, Inc.) diluted in PBS-gelatin for 1 h at room temperature. The slides were then incubated with 0.3% Sudan Black in 70% ethanol in order to reduce autofluorescence, washed two times, and mounted with Mowiol. Fluorescence analysis was performed using a confocal microscope (LSM 700; Carl Zeiss, Inc.) and Image analysis software.

Total RNA extraction and reverse transcription Total RNAs were extracted from small pieces of localized tumor using the PLAGyso Midi kit (QIAGEN) sold from bone marrow aspirates using the QIAamp RNA Blood kit (QIAGEN) according to the manufacturer’s instructions. Total RNA from human testis, dorsal root ganglion, prostate, bladder, colon, kidney, liver, lung, smooth muscle, heart, and brain was purchased from Takara Bia Inc., and subjected to reverse transcription as described in Bidaux et al. (2007).

Electrophysiology Macroscopic membrane ion currents were recorded at 37°C using the patch-clamp technique in its whole cell configuration. The currents were acquired using a PC9 amplifier (HEKA) in the case of whole-cell measurements and an Axopatch 200B amplifier (Molecular Devices), and analyzed offline using pClamp (Molecular Devices) and Origin software (OriginLab Corporation). The extracellular solution (osmolarity 310 mOsmol/liter) contained (in mM): 150 NaCl, 5 KCl, 10 HEPES, 10 Hepes, 1 MgCl₂, and 2 CaCl₂, pH 7.3 (adjusted with NaOH). The intracellular pipette solution (osmolarity 290 mOsmol/liter) contained (in mM): 140 CsCl, 10 Hepes, 8 EGTA, 1 MgCl₂, and 4 CaCl₂ (100 mM free Ca²⁺), pH 7.2 (adjusted with CsOH). Patch pipettes were made from borosilicate glass capillaries (WPI). The resistance of the pipettes varied between 3 and 5 MΩ. For single-channel analysis, the extracellular and pipette solutions contained (in mM): 150 KCl, 5 KCl, 10 Hepes, 1 CaCl₂, and 2 MgCl₂, pH 7.3 (adjusted with KOH) to bring the membrane potential close to zero and minimize junction potentials. Necessary supplements were added directly to the respective solutions at concentrations that would not significantly change the osmolality. Changes in the external solutions were performed using a multibarrel puffing micropipette with common outflow that was positioned in close proximity to the cell under investigation. During the experiment, the cell was continuously superfused with the solution via a puffing pipette to reduce possible artifacts related to the switch from static to moving solution and vice versa.

To achieve the expression of the TRPM8 channel with a plasma membrane density of one channel per patch on average, HEK-293ts cells were induced by 1 µl/ml tetracycline until the first open TRPM8 channels could be detected (typically 4 h, 20 min). To prevent the overexpression of the TRPM8 channel and avoid the appearance of multiple channels, the currents were recorded within 30 min of observation of the initial TRPM8 activity. Alternatively, HEK-293ts cells were treated with 1 µl/ml tetracycline for a short duration (typically 20 min). After this, cells were washed multiple times with fresh media and left overnight. Both approaches yielded identical TRPM8 currents.

The acquisition of TRPM8 activity was performed in cell-attached patches at room temperature (T = 20°C, controlled by a room thermostat). First, patches were subjected to a series of potentials ranging from −100 mV to 150 mV to assess the presence of the TRPM8 channel. Patches that contained TRPM8 activity were then recorded using an episodic stimulation protocol that held membrane potential at 100 mV for 10 s followed by the application of −30 mV for 2 s to prevent TRPM8 activity rundown. First, activity at room temperature was recorded, followed by the application of 100 µM menthol, to maximally stimulate TRPM8 channel.

Selection of traces suitable for single-channel analysis was performed by rejecting traces that at any point exhibited multiple simultaneous openings. Observing menthol-stimulated activity for at least 5 min
and taking mean open and closed dwell times to be 0.6 and 19 ms, respectively, the probability that two identical channels would never exhibit multiple conductance levels was \( \sim 10^{-10} \) (Baumgartner et al., 1997), which demonstrates the validity of this rejection criterion. Recorded activity was quantified by performing a single-channel search analysis using the Clampfit-10 program (pClamp software suite, Molecular Devices) and GBa.2.0 programs as described previously (Qin and Li, 2004; Fernández et al., 2011).

Imaging

Cytosolic Ca\(^{2+}\) concentrations were measured using the ratiometric dye Fura-2/AM (Invitrogen Ltd, UK) and quantified according to Grynkiewicz et al. (1985). Cells were loaded by a 50-min incubation of the cells with 5 µM fluo-4 acetoxy-methyl ester followed by a 60-min wash to allow time for de-esterification. Confocal [Ca\(^{2+}\)] imaging was performed as described previously (Povstyan et al., 2011; Shapovalov et al., 2013a). In brief, experimental chambers containing the cells were placed on the stage of an Axiovert 200M inverted microscope attached to an LSM 510 META laser-scanning unit (Carl Zeiss). x-y confocal images of fluo-4 fluorescence were acquired at 0.6 Hz using a Plan-Apochromat 40× 1.3 NA objective lens (Carl Zeiss). Fluo-4 fluorescence was excited by the 488 nm line of a 500 mW argon ion laser (Laser-Fertigung) and was captured at wavelengths >505 nm. The illumination intensity was attenuated to 0.6% with an acousto-optical tunable filter (Carl Zeiss). In all experiments, the photomultiplier gain was set at 688. To minimize signal quality, the pinhole was set to provide a confocal optical section <4 µm.

Time-lapse video microscopy

Cells were seeded at low density and kept at 37°C under 5% CO\(_2\) in an inverted microscope using a Plan-Apochromat 40× 1.3 NA objective lens (Carl Zeiss). Fluo-4 was loaded by a 50-min incubation of the cells with 5 µM fluo-4 acetoxy-methyl ester followed by a 60-min wash to allow time for de-esterification. Confocal [Ca\(^{2+}\)] imaging was performed as described previously (Povstyan et al., 2011; Shapovalov et al., 2013a). In brief, experimental chambers containing the cells were placed on the stage of an Axiovert 200M inverted microscope attached to an LSM 510 META laser-scanning unit (Carl Zeiss). x-y confocal images of fluo-4 fluorescence were acquired at 0.6 Hz using a Plan-Apochromat 40× 1.3 NA objective lens (Carl Zeiss). Fluo-4 fluorescence was excited by the 488 nm line of a 500 mW argon ion laser (Laser-Fertigung) and was captured at wavelengths >505 nm. The illumination intensity was attenuated to 0.6% with an acousto-optical tunable filter (Carl Zeiss). In all experiments, the photomultiplier gain was set at 688. To minimize signal quality, the pinhole was set to provide a confocal optical section <4 µm.

Fig. S3 shows that menthol-induced responses in human prostate epithelial cells are modulated by TCAF1 and TCAF2. Fig. S4 shows a sample activity of the TRPM8 channel. Fig. S5 depicts a comparison of the fit of control and TCAF1-bound TRPM8 activity to different kinetic models. Table S1 shows the full list of interacting peptides with TRPM8 channel, a summary of which can be found in Table S2. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201402076/DC1.

The authors would like to thank Prof. Varda Rotter for kindly providing the human epithelial prostate cells, Pip51T, Prof Viana and Prof. Parodi for kindly providing with prostate cell lines and input for the analysis of endogenous TRPM8 function analysis, and Prof. Thibault, W.J. Godello for the Original pm-trpousie2N1, pm-trpousie2C1, and pSYPFC2C1 vectors. This study was supported by grants from the French Ministère de l’Education Nationale and the Institut National de la Santé et de la Recherche Médicale. D. Gkika was supported by a long-term fellowship from the European Molecular Biology Organization (ALTF 161-2006) and the Institut National du Cancer (07/2D1611/PnAc-1018-V/GNC). M. Bernadini was supported by the Vinci PhD fellowship of the Frac-tional University (C3H3-64). D. Gordienko is supported by State Funds for Fundamental Research (f46 2/2001).

The authors declare no competing financial interests.

Submitted: 14 February 2014
Accepted: 1 December 2014

References


Published January 5, 2015

Identification of TRPM8 partner proteins • Gkika et al. 105

Downloaded from on March 6, 2017


Identification of TRPM8 partner proteins • Gkika et al.


Identification of TRPM8 partner proteins • Gkika et al. 107